Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.

Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA.

Circulation. 2004 Oct 12;110(15):2180-3. Epub 2004 Oct 4. Erratum in: Circulation. 2005 Jan 25;111(3):378.

2.

Angiotensin inhibition in heart failure.

McMurray JJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. Review.

PMID:
15526237
3.

Improving outcomes in chronic heart failure.

Komajda M.

Drugs Today (Barc). 2006 Dec;42 Suppl C:29-36. Review.

PMID:
17245479
4.

[CHARM study--new strategy for the treatment of heart failure].

Hasegawa H, Komuro I.

Nihon Rinsho. 2004 May;62(5):995-1002. Review. Japanese.

PMID:
15148833
6.

The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.

McKelvie RS.

Expert Rev Cardiovasc Ther. 2009 Jan;7(1):9-16. doi: 10.1586/14779072.7.1.9. Review.

PMID:
19105762
7.

Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Plosker GL, Keam SJ.

Pharmacoeconomics. 2006;24(12):1249-72. Review.

PMID:
17129078
8.

Candesartan cilexetil in the treatment of chronic heart failure.

Baguet JP, Barone-Rochette G, Neuder Y.

Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. Review.

9.

Exploring new treatment strategies in heart failure.

Swedberg K.

Blood Press Suppl. 2000;1:44-8. Review.

PMID:
11059637
10.

[Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].

Umemoto S, Matsuzaki M.

Nihon Rinsho. 2004 Jan;62(1):211-8. Review. Japanese.

PMID:
14737855
11.

Candesartan for the treatment of hypertension and heart failure.

Ostergren J.

Expert Opin Pharmacother. 2004 Jul;5(7):1589-97. Review.

PMID:
15212609
12.

Candesartan cilexetil: a review of its use in the management of chronic heart failure.

Fenton C, Scott LJ.

Drugs. 2005;65(4):537-58. Review.

PMID:
15733014
13.
14.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
15.

Candesartan for the management of heart failure: more than an alternative.

McKelvie RS.

Expert Opin Pharmacother. 2006 Oct;7(14):1945-56. Review.

PMID:
17020420
16.

Candesartan: from left ventricular hypertrophy to heart failure, a global approach.

Barrios V, Escobar C, Calderon A.

Expert Rev Cardiovasc Ther. 2007 Sep;5(5):825-34. Review. Erratum in: Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1171.

PMID:
17867913
17.

What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?

Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ.

J Am Coll Cardiol. 2012 Dec 11;60(23):2349-56. doi: 10.1016/j.jacc.2012.04.064. Epub 2012 Nov 7. Review.

18.

Candesartan in heart failure.

Ripley TL, Chonlahan JS, Germany RE.

Clin Interv Aging. 2006;1(4):357-66. Review.

19.

[Effect of angiotensin II receptor antagonist on heart failure].

Matsumori A.

Nihon Rinsho. 2004 Jan;62(1):203-10. Review. Japanese.

PMID:
14737854
20.

[Candesartan in heart failure: assessment of reduction in mortality and morbidity].

Tsutsui H.

Nihon Rinsho. 2007 Apr 28;65 Suppl 4:507-12. Review. Japanese. No abstract available.

PMID:
17508585

Supplemental Content

Support Center